This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Adobe, Abbott & Barrick Gold
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Systems (ADBE), Abbott Laboratories (ABT) and Barrick Gold (GOLD).
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect weak segmental performance.
Stryker (SYK) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 3.23% and 5.29%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Jul 30: BAX, SYK & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Earnings Preview: Stryker (SYK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs
by Sriparna Ghosal
Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.
Will Stryker (SYK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks
by Sriparna Ghosal
In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.
The Smart Future: Will Robotics Call the Shots Post Coronavirus?
by Zacks Equity Research
Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Why Is Stryker (SYK) Up 5% Since Last Earnings Report?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.
Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 8.88% and 5.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
Earnings Preview: Stryker (SYK) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
The Zacks Analyst Blog Highlights: SYK, SHOP, ATVI, TRP and DG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SYK, SHOP, ATVI, TRP and DG
Top Stock Reports for Stryker, Shopify & Activision Blizzard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Stryker (SYK), Shopify (SHOP) and Activision Blizzard (ATVI).
Why You Should Invest in Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
Here's Why You Should Hold On to Inogen (INGN) Stock for Now
by Zacks Equity Research
Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline
by Zacks Equity Research
Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.
Top 5 ROE Stocks to Buy as Markets Await Stimulus Package
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry ??? the higher, the better.